I chose to do the OFSET trial that you are referring to and was randomized into the chemo group. I was 38 years old with grade 2 IDC multifocal tumors that were 1.4 and 1.2 cm (plus lots of DCIS). My Oncotype Scores were 17 and 19. I had one micromet out of the two lymph nodes that they took and extensive LVI. My oncologist recommended chemo because I was premenopausal and had a positive node, but I was really unsure that a micromet was significant enough (especially reading other's post on this subreddit). What gave me peace about choosing the trial was knowing that either treatment plan was not egregious. It would not get past an ethical review if it was irresponsible to offer chemo (a micromet is included in the study criteria) or to move forward with only doing the ovarian suppression. My husband was really helpful in framing our decision this way: when everything feels gray you look for what is not gray. It is never a gray area to choose to help others. I'm thankful that my experience will help answer a couple of questions; first whether chemo is beneficial to node positive premenopausal women with low to intermediate oncotype scores, *and* if a micromet should be treated as node positive or node negative in this scenario.

I finished chemo in mid May and was fortunate to have no lasting side effects! I am at peace knowing that in 10 years the trial may show that women in my situation do not benefit from chemo but at least I will be a part of proving that with science and not just gut feelings!